Cost-Effectiveness Analysis of Pitavastatin in Dyslipidemia: Vietnam Case.

ABSTRACT: Background/Objectives: Dyslipidemia is becoming a significant economic healthcare burden in low- to middle-income countries (LMICs) due to its role in heightening cardiovascular-related mortality. Statins are the first-line treatment for reducing LDL-C levels, thereby minimizing direct costs associated with cardiovascular disease management, with pitavastatin being of the newest generation of statins. This research work conducted a cost-utility analysis of pitavastatin to determine the economic benefit in Vietnam. Methods: A decision tree model was developed to compare the rate of LDL-C controlled patients over a lifetime horizon among patients treated with pitavastatin, atorvastatin, and rosuvastatin. The primary outcome was the incremental cost-effectiveness ratio (ICER), m

SUBMITTER: Vo NX 

PROVIDER: S-EPMC12524106 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature